In Segment C, participants will receive ABBV-744 and oral navitoclax. In Segment D, participants will obtain ABBV-744 and ruxolitinib. Individuals will receive treatment until eventually disease progression or the participants are unable to tolerate the study drugs. after which encourage H3K27Ac at this area. Chromatin hyperacetylation could raise the accessibility https://abbv-744drugdevelopmentpr81345.is-blog.com/38337896/brd4-targeted-therapy-abbv-744-clinical-data-no-further-a-mystery